Loading…

Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone

BACKGROUND: Increased use of breast cancer screening has led to an increase in the number of diagnosed cases of ductal carcinoma in situ (DCIS). However, there is no definite way to predict progression or recurrence of DCIS. We analyzed the significance of biological markers and tumor characteristic...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2011-08, Vol.117 (16), p.3650-3657
Main Authors: Holmes, Phoebe, Lloyd, Joshua, Chervoneva, Inna, Pequinot, Edward, Cornfield, Dennis B., Schwartz, Gordon F., Allen, Kathleen G., Palazzo, Juan P.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3
cites cdi_FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3
container_end_page 3657
container_issue 16
container_start_page 3650
container_title Cancer
container_volume 117
creator Holmes, Phoebe
Lloyd, Joshua
Chervoneva, Inna
Pequinot, Edward
Cornfield, Dennis B.
Schwartz, Gordon F.
Allen, Kathleen G.
Palazzo, Juan P.
description BACKGROUND: Increased use of breast cancer screening has led to an increase in the number of diagnosed cases of ductal carcinoma in situ (DCIS). However, there is no definite way to predict progression or recurrence of DCIS. We analyzed the significance of biological markers and tumor characteristics in predicting recurrence in a large series of DCIS patients with long‐term follow‐up treated with breast conservation surgery (BCS) alone. METHODS: Clinical and pathological data were analyzed for 141 patients who underwent BCS for DCIS. All had negative surgical margins. Using local disease recurrence as an endpoint, we sought to determine the prognostic significance of several histopathological characteristics (tumor size, presence of necrosis, and subtype) and biological markers (estrogen receptor, progesterone receptor, and Her‐2/neu.) RESULTS: At a median follow‐up of 122 months (maximum follow‐up, 294 months), 60 recurrences occurred, with a median time to recurrence of 191 months. On multivariate analysis, Her‐2 positivity (3+) was found to be significantly associated with reduced time to tumor recurrence (P = .028). Tumor size and higher grade were marginally statistically significant (P = .099, P = .070). Neither necrosis nor tumor pathological characteristics were found to be significantly related to time to disease recurrence. CONCLUSIONS: Our results suggested that status of Her‐2/neu, larger tumor size, and higher nuclear grade were significantly correlated with time to tumor recurrence in patients treated with BCS alone. Using logistical analyses, no significant correlation was found between tumor pathological characteristics and disease recurrence. Cancer 2011. © 2011 American Cancer Society. We conducted a single‐institution analysis of several cases of breast ductal carcinoma in situ (DCIS) in which patients were treated with breast conservation surgery alone and followed up for as many as 24 years. Morphological features and prognostic markers were analyzed to determine their significance for predicting time to recurrence of DCIS.
doi_str_mv 10.1002/cncr.25942
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_881088016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>881088016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3</originalsourceid><addsrcrecordid>eNp9kMuKFTEQhoMozpnRjQ8g2Ygw0GOSTvqylIM3GFREwV1TXV2ZiXYnM0macXY-gs_ok5jjOerOVVHFx_9TH2OPpDiTQqhn6DGeKdNrdYdtpOjbSkit7rKNEKKrjK4_H7HjlL6UtVWmvs-OlKxlL43esOv3MVz4kLJDvkD8SjFx8BOfg7_4-f1HprjwsGYMCyXuPJ9WzDBzhIjOhwV2t-TyyoPl-ZL4GAlS5rmMTBO_cfmS0zd0yQXPoaTSA3bPwpzo4WGesE8vX3zcvq7O3716s31-XmFdPqk6rEeFRrbCgJyMafpGjJYmBT2OU9_CqGlEW3eadG2bRis7WmwN6tZA30B9wp7uc69iuF4p5WFxCWmewVNY09B1UnSdkE0hT_ckxpBSJDtcRVdk3A5SDDvDw87w8NtwgR8fYtdxoekv-kdpAZ4cAEgIs43gy_v_OK1F0xhROLnnbtxMt_-pHLZvtx_25b8A1_6WPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881088016</pqid></control><display><type>article</type><title>Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone</title><source>Wiley</source><source>EZB Electronic Journals Library</source><creator>Holmes, Phoebe ; Lloyd, Joshua ; Chervoneva, Inna ; Pequinot, Edward ; Cornfield, Dennis B. ; Schwartz, Gordon F. ; Allen, Kathleen G. ; Palazzo, Juan P.</creator><creatorcontrib>Holmes, Phoebe ; Lloyd, Joshua ; Chervoneva, Inna ; Pequinot, Edward ; Cornfield, Dennis B. ; Schwartz, Gordon F. ; Allen, Kathleen G. ; Palazzo, Juan P.</creatorcontrib><description>BACKGROUND: Increased use of breast cancer screening has led to an increase in the number of diagnosed cases of ductal carcinoma in situ (DCIS). However, there is no definite way to predict progression or recurrence of DCIS. We analyzed the significance of biological markers and tumor characteristics in predicting recurrence in a large series of DCIS patients with long‐term follow‐up treated with breast conservation surgery (BCS) alone. METHODS: Clinical and pathological data were analyzed for 141 patients who underwent BCS for DCIS. All had negative surgical margins. Using local disease recurrence as an endpoint, we sought to determine the prognostic significance of several histopathological characteristics (tumor size, presence of necrosis, and subtype) and biological markers (estrogen receptor, progesterone receptor, and Her‐2/neu.) RESULTS: At a median follow‐up of 122 months (maximum follow‐up, 294 months), 60 recurrences occurred, with a median time to recurrence of 191 months. On multivariate analysis, Her‐2 positivity (3+) was found to be significantly associated with reduced time to tumor recurrence (P = .028). Tumor size and higher grade were marginally statistically significant (P = .099, P = .070). Neither necrosis nor tumor pathological characteristics were found to be significantly related to time to disease recurrence. CONCLUSIONS: Our results suggested that status of Her‐2/neu, larger tumor size, and higher nuclear grade were significantly correlated with time to tumor recurrence in patients treated with BCS alone. Using logistical analyses, no significant correlation was found between tumor pathological characteristics and disease recurrence. Cancer 2011. © 2011 American Cancer Society. We conducted a single‐institution analysis of several cases of breast ductal carcinoma in situ (DCIS) in which patients were treated with breast conservation surgery alone and followed up for as many as 24 years. Morphological features and prognostic markers were analyzed to determine their significance for predicting time to recurrence of DCIS.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.25942</identifier><identifier>PMID: 21319154</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor - analysis ; breast conservation surgery ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Ductal, Breast - surgery ; Carcinoma, Intraductal, Noninfiltrating - surgery ; ductal carcinoma in situ ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local ; Prognosis ; prognostic markers ; Receptor, ErbB-2 - analysis ; Treatment Outcome ; Tumors</subject><ispartof>Cancer, 2011-08, Vol.117 (16), p.3650-3657</ispartof><rights>Copyright © 2011 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3</citedby><cites>FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24406650$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21319154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holmes, Phoebe</creatorcontrib><creatorcontrib>Lloyd, Joshua</creatorcontrib><creatorcontrib>Chervoneva, Inna</creatorcontrib><creatorcontrib>Pequinot, Edward</creatorcontrib><creatorcontrib>Cornfield, Dennis B.</creatorcontrib><creatorcontrib>Schwartz, Gordon F.</creatorcontrib><creatorcontrib>Allen, Kathleen G.</creatorcontrib><creatorcontrib>Palazzo, Juan P.</creatorcontrib><title>Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND: Increased use of breast cancer screening has led to an increase in the number of diagnosed cases of ductal carcinoma in situ (DCIS). However, there is no definite way to predict progression or recurrence of DCIS. We analyzed the significance of biological markers and tumor characteristics in predicting recurrence in a large series of DCIS patients with long‐term follow‐up treated with breast conservation surgery (BCS) alone. METHODS: Clinical and pathological data were analyzed for 141 patients who underwent BCS for DCIS. All had negative surgical margins. Using local disease recurrence as an endpoint, we sought to determine the prognostic significance of several histopathological characteristics (tumor size, presence of necrosis, and subtype) and biological markers (estrogen receptor, progesterone receptor, and Her‐2/neu.) RESULTS: At a median follow‐up of 122 months (maximum follow‐up, 294 months), 60 recurrences occurred, with a median time to recurrence of 191 months. On multivariate analysis, Her‐2 positivity (3+) was found to be significantly associated with reduced time to tumor recurrence (P = .028). Tumor size and higher grade were marginally statistically significant (P = .099, P = .070). Neither necrosis nor tumor pathological characteristics were found to be significantly related to time to disease recurrence. CONCLUSIONS: Our results suggested that status of Her‐2/neu, larger tumor size, and higher nuclear grade were significantly correlated with time to tumor recurrence in patients treated with BCS alone. Using logistical analyses, no significant correlation was found between tumor pathological characteristics and disease recurrence. Cancer 2011. © 2011 American Cancer Society. We conducted a single‐institution analysis of several cases of breast ductal carcinoma in situ (DCIS) in which patients were treated with breast conservation surgery alone and followed up for as many as 24 years. Morphological features and prognostic markers were analyzed to determine their significance for predicting time to recurrence of DCIS.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>breast conservation surgery</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Ductal, Breast - surgery</subject><subject>Carcinoma, Intraductal, Noninfiltrating - surgery</subject><subject>ductal carcinoma in situ</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Prognosis</subject><subject>prognostic markers</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kMuKFTEQhoMozpnRjQ8g2Ygw0GOSTvqylIM3GFREwV1TXV2ZiXYnM0macXY-gs_ok5jjOerOVVHFx_9TH2OPpDiTQqhn6DGeKdNrdYdtpOjbSkit7rKNEKKrjK4_H7HjlL6UtVWmvs-OlKxlL43esOv3MVz4kLJDvkD8SjFx8BOfg7_4-f1HprjwsGYMCyXuPJ9WzDBzhIjOhwV2t-TyyoPl-ZL4GAlS5rmMTBO_cfmS0zd0yQXPoaTSA3bPwpzo4WGesE8vX3zcvq7O3716s31-XmFdPqk6rEeFRrbCgJyMafpGjJYmBT2OU9_CqGlEW3eadG2bRis7WmwN6tZA30B9wp7uc69iuF4p5WFxCWmewVNY09B1UnSdkE0hT_ckxpBSJDtcRVdk3A5SDDvDw87w8NtwgR8fYtdxoekv-kdpAZ4cAEgIs43gy_v_OK1F0xhROLnnbtxMt_-pHLZvtx_25b8A1_6WPA</recordid><startdate>20110815</startdate><enddate>20110815</enddate><creator>Holmes, Phoebe</creator><creator>Lloyd, Joshua</creator><creator>Chervoneva, Inna</creator><creator>Pequinot, Edward</creator><creator>Cornfield, Dennis B.</creator><creator>Schwartz, Gordon F.</creator><creator>Allen, Kathleen G.</creator><creator>Palazzo, Juan P.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110815</creationdate><title>Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone</title><author>Holmes, Phoebe ; Lloyd, Joshua ; Chervoneva, Inna ; Pequinot, Edward ; Cornfield, Dennis B. ; Schwartz, Gordon F. ; Allen, Kathleen G. ; Palazzo, Juan P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>breast conservation surgery</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Ductal, Breast - surgery</topic><topic>Carcinoma, Intraductal, Noninfiltrating - surgery</topic><topic>ductal carcinoma in situ</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Prognosis</topic><topic>prognostic markers</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holmes, Phoebe</creatorcontrib><creatorcontrib>Lloyd, Joshua</creatorcontrib><creatorcontrib>Chervoneva, Inna</creatorcontrib><creatorcontrib>Pequinot, Edward</creatorcontrib><creatorcontrib>Cornfield, Dennis B.</creatorcontrib><creatorcontrib>Schwartz, Gordon F.</creatorcontrib><creatorcontrib>Allen, Kathleen G.</creatorcontrib><creatorcontrib>Palazzo, Juan P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holmes, Phoebe</au><au>Lloyd, Joshua</au><au>Chervoneva, Inna</au><au>Pequinot, Edward</au><au>Cornfield, Dennis B.</au><au>Schwartz, Gordon F.</au><au>Allen, Kathleen G.</au><au>Palazzo, Juan P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2011-08-15</date><risdate>2011</risdate><volume>117</volume><issue>16</issue><spage>3650</spage><epage>3657</epage><pages>3650-3657</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND: Increased use of breast cancer screening has led to an increase in the number of diagnosed cases of ductal carcinoma in situ (DCIS). However, there is no definite way to predict progression or recurrence of DCIS. We analyzed the significance of biological markers and tumor characteristics in predicting recurrence in a large series of DCIS patients with long‐term follow‐up treated with breast conservation surgery (BCS) alone. METHODS: Clinical and pathological data were analyzed for 141 patients who underwent BCS for DCIS. All had negative surgical margins. Using local disease recurrence as an endpoint, we sought to determine the prognostic significance of several histopathological characteristics (tumor size, presence of necrosis, and subtype) and biological markers (estrogen receptor, progesterone receptor, and Her‐2/neu.) RESULTS: At a median follow‐up of 122 months (maximum follow‐up, 294 months), 60 recurrences occurred, with a median time to recurrence of 191 months. On multivariate analysis, Her‐2 positivity (3+) was found to be significantly associated with reduced time to tumor recurrence (P = .028). Tumor size and higher grade were marginally statistically significant (P = .099, P = .070). Neither necrosis nor tumor pathological characteristics were found to be significantly related to time to disease recurrence. CONCLUSIONS: Our results suggested that status of Her‐2/neu, larger tumor size, and higher nuclear grade were significantly correlated with time to tumor recurrence in patients treated with BCS alone. Using logistical analyses, no significant correlation was found between tumor pathological characteristics and disease recurrence. Cancer 2011. © 2011 American Cancer Society. We conducted a single‐institution analysis of several cases of breast ductal carcinoma in situ (DCIS) in which patients were treated with breast conservation surgery alone and followed up for as many as 24 years. Morphological features and prognostic markers were analyzed to determine their significance for predicting time to recurrence of DCIS.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21319154</pmid><doi>10.1002/cncr.25942</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2011-08, Vol.117 (16), p.3650-3657
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_881088016
source Wiley; EZB Electronic Journals Library
subjects Biological and medical sciences
Biomarkers, Tumor - analysis
breast conservation surgery
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - pathology
Carcinoma, Ductal, Breast - surgery
Carcinoma, Intraductal, Noninfiltrating - surgery
ductal carcinoma in situ
Female
Follow-Up Studies
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Neoplasm Recurrence, Local
Prognosis
prognostic markers
Receptor, ErbB-2 - analysis
Treatment Outcome
Tumors
title Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A05%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20markers%20and%20long%E2%80%90term%20outcomes%20in%20ductal%20carcinoma%20in%20situ%20of%20the%20breast%20treated%20with%20excision%20alone&rft.jtitle=Cancer&rft.au=Holmes,%20Phoebe&rft.date=2011-08-15&rft.volume=117&rft.issue=16&rft.spage=3650&rft.epage=3657&rft.pages=3650-3657&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.25942&rft_dat=%3Cproquest_cross%3E881088016%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3942-8c3b2c51705a1d556960bfed2a9cbd97ab4ebcf384e43f6642fbfc75c475a96a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=881088016&rft_id=info:pmid/21319154&rfr_iscdi=true